Over an 24-month period approximately.

announced today that it has obtained a committed collateral financing service under which it may sell up to $20 million of its authorized common share to Azimuth Opportunity, L.P., over an 24-month period approximately. King, President and CEO of Alexza.’ Alexza will determine, at its sole discretion, the timing, the dollar amount and the ground price per talk about of every draw under this facility, subject to certain circumstances. Alexza issued 80 also,429 shares of common stock to Azimuth as factor for getting into the facility..The first medical center to enroll people into the trial may be the Christ Hospital Heart and Vascular Center and The Lindner Study Center in Cincinnati, Ohio. The ABSORB IV trial is an important step forward in identifying the relative scientific benefits linked to the dissolvable device compared with the permanent metallic stent, stated Dean Kereiakes, M.D., FACC, FSCAI, medical director, The Christ Hospital Center and Vascular Center and The Lindner Research Center, and nationwide co-principal investigator of the ABSORB IV trial.